HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Quinn, N. Articles by Agid, Y. Search for Related Content PubMed PubMed Citation Articles by Quinn, N. Articles by Agid, Y.

Bromocriptine and domperidone in the treatment of Parkinson disease

From the Clinique de Neurologie et Neuropsychologie, Hôpital de la Salpétrière, Paris, France.

In a single-blind trial of therapy in 20 patients with idiopathic Parkinson disease, domperidone prevented nausea and vomiting induced by bromocriptine without diminishing beneficial central effects. Combination of the two drugs permitted rapid increase in bromocriptine dosage from 22.5 mg per day to 148 mg per day, with 71% mean clinical improvement over baseline score; continuing efficacy of the regimen was evident for a mean follow-up of 2 months.

Address correspondence and reprint requests to Dr. Agid, Clinique de Neurologie et Neuropsychologie, Hôpital de la Salpétrière, 75634, Paris Cedex 13, France.

Accepted for publication September 23, 1980.

This article has been cited by other articles:

				U. Lertxundi, J. Peral, O. Mora, S. Domingo-Echaburu, M. J. Martinez-Bengoechea, and J. C. Garcia-Monco Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease Am. J. Health Syst. Pharm., March 1, 2008; 65(5): 414 - 419. [Abstract] [Full Text] [PDF]